Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement

Allergic rhinitis (AR) affects 23–30% of the European population with equal prevalence reported in Belgium. Despite guidelines on the correct use of effective treatment, up to 40% of AR patients remain uncontrolled. Allergen immunotherapy (AIT) has been shown to improve the level of control up to 84...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellings, P. W., Pugin, B., Mariën, G., Bachert, C., Breynaert, C., Bullens, D. M., Ceuppens, J. L., Clement, G., Cox, T., Ebo, D., Gevaert, P., Halewyck, S., Hox, V., Ladha, K., Jacobs, R., Rombaux, P., Schrijvers, R., Speleman, K., Van der Brempt, X., Van Gerven, L., Vanderveken, O., Verhaeghe, B., Vierstraete, K., Vlaminck, S., Watelet, J. -B., Bousquet, J., Seys, S. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360767/
https://www.ncbi.nlm.nih.gov/pubmed/30740211
http://dx.doi.org/10.1186/s13601-019-0243-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360767/
https://www.ncbi.nlm.nih.gov/pubmed/30740211
http://dx.doi.org/10.1186/s13601-019-0243-1

Ejemplares similares